304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)

A. Okines; G. Curigliano; N. Mizuno; D-Y. Oh; A. Rorive; H. Soliman; S. Takahashi; T. Bekaii-Saab; E.P. Hamilton; B.J. Monk; Y. Nakamura; D. Nguyen; D. O'Malley; M. Reck; E. Yu; A. Drees; J.D. Ramos; Q. Tan; T. Stinchcombe; P.R. Pohlmann

doi:10.1016/j.esmoop.2025.104876

Back

304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)

Journal article

Peer reviewed

304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)

A. Okines, G. Curigliano, N. Mizuno, D-Y. Oh, A. Rorive, H. Soliman, S. Takahashi, T. Bekaii-Saab, E.P. Hamilton, B.J. Monk, …

ESMO open, Vol.10, p.104876

05/2025

DOI: https://doi.org/10.1016/j.esmoop.2025.104876

Files and links (1)

url

https://doi.org/10.1016/j.esmoop.2025.104876View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
Creators: A. Okines - Royal Marsden Hospital
G. Curigliano - Department of Oncology and Hemato-Oncology, Istituto Europeo di Oncologia, IRCCS and University of Milano, Milan, Italy
N. Mizuno - Aichi Cancer Center
D-Y. Oh - Seoul National University Hospital
A. Rorive - Department of Medical Oncology, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium
H. Soliman - Moffitt Cancer Center
S. Takahashi - Department of Medical Oncology, The Cancer Institute Hospital of JFCR, Koto-ku, Japan
T. Bekaii-Saab - Department of Medical Oncology, Mayo Clinic Cancer Center, Phoenix, United States of America
E.P. Hamilton - Sarah Cannon Research Institute
B.J. Monk - Gynecologic Oncology Department, Florida Cancer Specialists and Research Institute, West Palm Beach, FL, United States of America
Y. Nakamura - Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
D. Nguyen - Hematology and Oncology Department, City of Hope Comprehensive Cancer Center, Duarte, United States of America
D. O'Malley - The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
M. Reck - Department of Thoracic Oncology, Airway Research Center North, Germany Center for Lung Disease, Grosshansdorf, Germany
E. Yu - University of Washington
A. Drees - Clinical Development, Pfizer Inc., Bothell, United States of America
J.D. Ramos - Clinical Development, Pfizer Inc., Bothell, United States of America
Q. Tan - Biostatistics, Pfizer Inc., Bothell, United States of America
T. Stinchcombe - Medical Oncology Department, Duke Cancer Center, Durham, United States of America
P.R. Pohlmann - The University of Texas MD Anderson Cancer Center
Publication Details: ESMO open, Vol.10, p.104876
Publisher: Elsevier Ltd
Identifiers: 991006169418702656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article